US stock futures flounder amid tech weakness, Fed caution
On Monday, Cantor Fitzgerald highlighted the varying performances within the medical devices and supplies sector. Elutia, trading under the ticker (NASDAQ:ELUT), emerged as the top performer last week, with its shares climbing 14.6% to $4.52. According to InvestingPro analysis, the stock appears fairly valued at current levels. In contrast, Anteris Technologies, listed as (NASDAQ:AVR), experienced a decline, with its stock value dropping 9.3%.
The industry newsletter, which was released on Saturday, March 15, 2025, also shed light on the quarterly and year-to-date (YTD) standings of companies within the sector. MIMEDX Group Inc. (NASDAQ:MDXG) saw a significant surge in the fourth quarter of 2024, with its stock rising 62.8% quarter-to-date (QTD). Nyxoah SA (NASDAQ:NYXH) did not fare as well, with its shares falling 16.2%, making it the weakest performer in the same period. InvestingPro data shows the company maintains a FAIR Financial Health Score of 2.1, with revenue of $25.56M in the last twelve months.
Cantor Fitzgerald’s coverage also revealed that Organogenesis Holdings Inc. (NASDAQ:ORGO) has had an impressive run so far this year, with its stock price up by 56.6% YTD. On the other end of the spectrum, AVITA Medical (TASE:BLWV) Inc. (NASDAQ:RCEL) has seen its shares decrease by 33.2% since the beginning of the year. Investors following these companies should note that the next earnings release is scheduled for April 4, 2025, with analysts maintaining a Strong Buy consensus.
Want deeper insights into medical device stocks? InvestingPro subscribers get access to exclusive financial metrics, Fair Value assessments, and comprehensive analyst forecasts.
The medical devices and supplies sector encompasses a wide range of companies, each with unique trajectories. The performance of these companies is closely monitored by industry analysts, as their stock movements can indicate broader trends within the healthcare market. The recent updates provided by Cantor Fitzgerald serve as a snapshot of the sector’s current dynamics, offering investors insight into which companies are gaining momentum and which are facing challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.